PMID- 31920286
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20220412
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 13
DP  - 2019
TI  - Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept 
      Injection for Diabetic Macular Edema.
PG  - 4367-4374
LID - 10.2147/DDDT.S222004 [doi]
AB  - PURPOSE: This study aimed to investigate the concentrations of cytokines and 
      chemokines in diabetic macular edema (DME) eyes before and during therapy with 
      the intravitreal injection of conbercept (IVC) and to identify associations with 
      disease activity. METHODS: The Bio-Plex((R)) 200 System and the Bio-PlexTM Human 
      Cytokine Standard 27-Plex, Group I (Bio-Rad, Hercules, California, USA) were used 
      to detect cytokine levels in aqueous humour. Experimental aqueous humour samples 
      were collected from 18 patients with DME at the same time that IVC was performed 
      at baseline and at 1 month. Control aqueous humour samples were collected from 16 
      patients undergoing cataract surgery. RESULTS: Significantly higher 
      concentrations of vascular endothelial growth factor (VEGF), interleukin 6 
      (IL-6), IL-8, eotaxin, granulocyte colony stimulating factor (G-CSF), interferon 
      gamma-induced protein 10 (IP-10), and monocyte chemoattractant protein-1 (MCP-1) 
      were found in the aqueous humour of DME patients than cataract patients. One 
      month after IVC, the intraocular concentrations of VEGF were significantly lower 
      in the eyes of DME patients than at baseline. No other cytokines were 
      significantly altered by conbercept therapy. Best-corrected visual acuity (BCVA) 
      slightly improved following IVC compared with that at baseline, although this 
      difference was not significant, and central macular thickness (CMT) significantly 
      decreased 1 month after IVC treatment. CONCLUSION: Angiogenic, inflammatory and 
      growth factors are involved in the development of DME. With the exception of 
      VEGF, IVC did not cause significant differences in any inflammatory cytokines or 
      growth factors in DME patients. CMT is related to VEGF levels in aqueous humour.
CI  - (c) 2019 Wei et al.
FAU - Wei, Qingquan
AU  - Wei Q
AD  - Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University, 
      Shanghai 200072, People's Republic of China.
FAU - Wan, Zhongqi
AU  - Wan Z
AD  - School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu 
      Province, People's Republic of China.
FAU - Hu, Yongcheng
AU  - Hu Y
AD  - Department of Ophthalmology, Bayannuer Paralympic Eye Hospital, Inner Mongolia 
      015000, People's Republic of China.
FAU - Peng, Qing
AU  - Peng Q
AD  - Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University, 
      Shanghai 200072, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20191224
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Cytokines)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 1P05PW62F3 (KH902 fusion protein)
SB  - IM
MH  - Angiogenesis Inhibitors/administration & dosage/*therapeutic use
MH  - Cytokines/*analysis/metabolism
MH  - Diabetic Retinopathy/*drug therapy
MH  - Female
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Recombinant Fusion Proteins/administration & dosage/*metabolism
PMC - PMC6935285
OTO - NOTNLM
OT  - conbercept
OT  - diabetic macular oedema
OT  - intraocular cytokines
OT  - intravitreal implant
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/01/11 06:00
MHDA- 2020/06/18 06:00
PMCR- 2019/12/24
CRDT- 2020/01/11 06:00
PHST- 2019/07/05 00:00 [received]
PHST- 2019/12/05 00:00 [accepted]
PHST- 2020/01/11 06:00 [entrez]
PHST- 2020/01/11 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PHST- 2019/12/24 00:00 [pmc-release]
AID - 222004 [pii]
AID - 10.2147/DDDT.S222004 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2019 Dec 24;13:4367-4374. doi: 10.2147/DDDT.S222004. 
      eCollection 2019.